Marc Raaijmakers received a check of € 55.000,- at the Dutch Hematology Conference from Gijs Beukhof of the Leukemia Foundation (see here). A fantastic amount that allows us to take another step forward in the research into ALL.
With this funding, we aim to map the immune microenvironment of B-cell ALL and discover predictors for response and toxicity to blinatumomab.
This project will be carried out in the laboratory of both the Hematology and Immunology departments of Erasmus MC by Eske van Baalen, Rosan Olsman, Vincent van der Velden, Marc Raaijmakers, and Anita Rijneveld.
They aim to answer the following questions:
- What does the immune microenvironment (consisting of stromal, NK, T, and other immune cells) in B-ALL look like at the cellular level, and how do these cells interact with leukemia and non-leukemic cells?
- Is this composition of the microenvironment in patients with B-ALL associated with the response to blinatumomab?
- Is the composition of the microenvironment in patients with B-ALL associated with the development of side effects, i.e., cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)?
Reactie plaatsen
Reacties